PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma
Public ClinicalTrials.gov record NCT03269136. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
MAGNETISMM-1 A PHASE I, OPEN LABEL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETIC, PHARMACODYNAMIC AND CLINICAL ACTIVITY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA) - CD3 BISPECIFIC ANTIBODY, AS A SINGLE AGENT AND IN COMBINATION WITH IMMUNOMODULATORY AGENTS IN PATIENTS WITH RELAPSED/REFRACTORY ADVANCED MULTIPLE MYELOMA (MM)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To assess the safety and tolerability at increasing dose levels of PF-06863135 in patients with relapse/ refractory multiple myeloma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
Study identification
- NCT ID
- NCT03269136
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 101 participants
Conditions and interventions
Conditions
Interventions
- PF-06863135 monotherapy IV or SC Drug
- PF-06863135 + dexamethasone Drug
- PF-06863135 + lenalidomide Drug
- PF-06863135 + pomalidomide Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 29, 2017 (Actual)
- Primary completion
- Jan 19, 2024 (Actual)
- Completion
- Jan 19, 2024 (Actual)
- Last update posted
- Mar 18, 2025
2017 – 2024
United States locations
- U.S. sites
- 32
- U.S. states
- 11
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCSD Medical Center - Encinitas | Encinitas | California | 92024 | — |
| UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Hospital) | La Jolla | California | 92037 | — |
| UC San Diego Moores Cancer Center | La Jolla | California | 92037 | — |
| UC San Diego Medical Center - Hillcrest | San Diego | California | 92103 | — |
| UCSD Medical Center - Vista | Vista | California | 92081 | — |
| Blood and Marrow Transplant Group of Georgia | Atlanta | Georgia | 30342 | — |
| Northside Hospital | Atlanta | Georgia | 30342 | — |
| UChicago Medicine - River East | Chicago | Illinois | 60611 | — |
| The University of Chicago Medical Center, CCD - Investigational Drug Service Pharmacy | Chicago | Illinois | 60637 | — |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| UChicago Medicine at Ingalls - Flossmoor | Flossmoor | Illinois | 60422 | — |
| UChicago Medicine Ingalls Memorial | Harvey | Illinois | 60426 | — |
| University of Chicago Comprehensive Cancer Center at Silver Cross Hospital | New Lenox | Illinois | 60451 | — |
| The University of Chicago Medicine Center for Advanced Care Orland Park | Orland Park | Illinois | 60462 | — |
| UChicago Medicine at Ingalls - Tinley Park | Tinley Park | Illinois | 60477 | — |
| University of Iowa Hospitals and Clinics | Iowa City | Iowa | 52242 | — |
| Ochsner Clinic Foundation | New Orleans | Louisiana | 70121 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Memorial Sloan Kettering Cancer Center at Basking Ridge | Basking Ridge | New Jersey | 07920 | — |
| Memorial Sloan Kettering Cancer Center at Monmouth | Middletown | New Jersey | 07748 | — |
| Memorial Sloan Kettering Cancer Center at Bergen | Montvale | New Jersey | 07645 | — |
| Memorial Sloan Kettering Cancer Center at Commack | Commack | New York | 11725 | — |
| Memorial Sloan Kettering Cancer Center at Westchester | Harrison | New York | 10604 | — |
| Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care | New York | New York | 10021 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Memorial Sloan Kettering Cancer Center at Nassau | Uniondale | New York | 11553 | — |
| Duke University Health System: Adult Bone Marrow Transplant Clinic | Durham | North Carolina | 27705 | — |
| Duke Cancer Center | Durham | North Carolina | 27710 | — |
| Duke University Hospital | Durham | North Carolina | 27710 | — |
| Henry Joyce Cancer Center | Nashville | Tennessee | 37232 | — |
| Baylor University Medical Center | Dallas | Texas | 75246 | — |
| Investigational Drug Services, Baylor University Medical Center | Dallas | Texas | 75246 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03269136, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 18, 2025 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03269136 live on ClinicalTrials.gov.